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Astrocytes play a critical role during the development and the maintenance of the CNS in health and disease. Yet, their lack of
accessibility from fetuses and from the brain of diseased patients has hindered our understanding of their full implication in
developmental and pathogenic processes. Human pluripotent stem cells (PSCs) are an alternative source to obtain large
quantities of astrocytes in vitro, for mechanistic studies of development and disease. However, these studies often require
highly pure populations of astrocytes, which are not always achieved, depending on the PSC lines and protocols used. Here, we
describe the generation and characterization of human PSC reporter lines expressing TagRFP driven by the ABC1D region of the
human GFAP promoter, as new cellular model for generating homogenous population of astrocytes generated from
CNS regionally defined PSC-derived neural progenitors. GFAABC1D::TagRFP-expressing astrocytes can be purified by
fluorescent-activated cell sorting and maintain a bright expression for several additional weeks. These express canonical
astrocyte markers NF1A, S100β, CX43, GLAST, GS and CD44. These new cellular models, from which highly pure populations of⁎ Corresponding author at: Stem Cell Laboratory for CNS Disease Modeling, Department of Experimental Science, MultiPark and Lund Stem
Cell Center, Lund University, BMC A10, Sölvegatan 19, SE-221 84 Lund, Sweden.
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204 S. Holmqvist et al.fluorescence-expressing astrocytes can be obtained, provide a new platform for studies where pure or fluorescently labeled
astrocyte populations are necessary, for example to assess pro-inflammatory cytokine and chemokine release in response to
specific treatment, and uptake and degradation of fluorescently labeled pathogenic proteins, as reported in this study.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Astrocytes are the most abundant cell type in the human
brain. They play a critical role in the maintenance of
homeostasis of the central nervous system (CNS) by a wide
spectrum of functions. These functions include, but are not
restricted to, regulation of blood flow (Attwell et al., 2010),
regulation of energy reserves (Choi et al., 2012), modulation
of synaptic transmission (Simard and Nedergaard, 2004),
neuronal connectivity (Eroglu and Barres, 2010), and uptake
of potentially pathogenic proteins (Lee et al., 2010;
Wakabayashi et al., 2000). Furthermore, astrocytes can be
triggered by environmental cues including cytokines and
chemokines to become reactive during brain injury (Chen
and Swanson, 2003) and neurodegenerative diseases, such as
amyotrophic lateral sclerosis (Haidet-Phillips et al., 2011;
Yamanaka et al., 2008) and Parkinson's disease (Waak et al.,
2009). Although these reactive astrocytes are thought to have
a neuroprotective function, astrocyte reactivity has also been
associated with neurotoxicity (Chao et al., 1996; Episcopo et
al., 2013; Lee et al., 2013; Pekny et al., 2014); the
mechanisms of balance between neuroprotection and neuro-
toxicity are still not well understood.
During human brain development, neuroepithelial cells
are subject to regional patterning through the effects of
morphogens such as retinoic acid (RA) or sonic hedgehog
(SHH) (Kiecker and Lumsden, 2012; Rowitch and Kriegstein,
2010). Neuroepithelial cells have the potential to differen-
tiate into glial cell types (astrocytes and oligodendrocytes)
and distinct neuronal subtypes characterized by the neuro-
transmitter they release and expression of regional identity
markers. Recent work has evidenced that positional diver-
sity also exists among astrocytes (Tsai et al., 2012), there-
fore raising a growing interest in the effects of patterning
factors during the development of astrocytes. Moreover,
there is increasing evidence that astrocytes may differ
between brain structures, and within these structures,
depending on their location along the dorso-ventral and
rostro-caudal axis (Anderson et al., 2014; Bachoo et al.,
2004; Chaboub and Deneen, 2012). Because primary human
material is not always accessible, advance in the under-
standing of astrocyte development and diversity has mainly
been based on observations in rodent models (Deneen et al.,
2006; Hochstim et al., 2008), and it is only recently that
investigations using human astrocytes have been made to
better characterize their functional properties, in vivo (Han
et al., 2013; Oberheim et al., 2009).
One of the few feasible sources to investigate human
astrocyte development and function in health and disease is
via human pluripotent stem cells (PSCs). Human PSCs include
embryonic stem cells (ESCs) and induced pluripotent stem
cells (iPSCs) which often are the primary source of material
used to study neuronal subtypes in vitro using protocols that
include time-specific exposure to patterning cues followingdevelopmental principles (Hu et al., 2010; Swistowski et al.,
2010). Recently, different protocols have also been de-
scribed for the differentiation of human PSCs into regional-
ized astrocytes in vitro (Jiang et al., 2013; Juopperi et al.,
2012; Kondo et al., 2013; Krencik et al., 2011; Roybon et al.,
2013; Serio et al., 2013; Shaltouki et al., 2013; Yuan et al.,
2011). However, as opposed to the multitude developed for
generating spinal cord astrocytes (Jiang et al., 2013; Krencik
et al., 2011; Roybon et al., 2013; Serio et al., 2013), only
few exist for generating forebrain and midbrain astrocytes
(Juopperi et al., 2012; Kondo et al., 2013; Krencik et al.,
2011). The efficiency of these protocols to generate astro-
cytes, however, varies greatly not only depending on the type
of PSCs primarily used, but also in-between individual iPSC
lines generated from one or multiple patients. With PSC
technologies potential to personalize medical therapy in the
near future, there is a need for tools that can provide a
reliable source of homogenous astrocyte populations, regard-
less of the primary material, enabling development of cellular
models for the study of astrocytes maintenance of brain
homeostasis in health and disease.
Acquiring an enriched population of a given cell type
using a fluorescence-based reporter line has many advan-
tages but requires that the reporter expression is specific to
the cell type to be enriched. Glial fibrillary acidic protein
(GFAP) is a well-known marker for astrocytes; its expression
is dynamic, and associated with astrocyte differentiation
(Brenner, 1994; Lee et al., 2008) and known to be
up-regulated in reactive astrocytes, in vitro. Therefore,
the GFAP promoter is a good candidate for the generation of
astrocyte specific reporter lines for use in developmental
and disease related in vitro studies. The human GFAP
promoter consists of four distinct domains: A, B, C and D
(Lee et al., 2008). Exclusion of the entire C-domain results in
misexpression of GFAP and loss of astrocyte specific expression
while maintenance of one of the six C-subdomains, the
C1-subdomain, allows astrocyte specific expression of GFAP
throughout the CNS. Notably, this GFAABC1D element of the
GFAP promoter is advantageous not only because of its
reduced size but also since reporter driven expression by the
GFAABC1D promoter was shown to be more efficiently expressed
compared to when driven by the full size promoter (Lee et al.,
2008). This streamlined promoter was previously successfully
used to direct enhanced green fluorescent protein and short
hairpin RNA in astrocytes (Yan et al., 2012).
In this study, we engineered human PSCs to express
the monomeric red fluorescent protein (TagRFP) under
the control of the human GFAABC1D promoter fragment
(GFAABC1D::TagRFP). We initiated our work in human ESCs,
and validated the reporter expression in astrocytes gener-
ated from human ESC-derived midbrain and spinal cord
progenitors. Furthermore, we show that labeled astrocytes
aged 90 DIV can be purified by FACS, and kept for an
additional 40 days in vitro with no dramatic loss of reporter
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purified labeled astrocytes by immunocytochemistry for
known astroglial markers nuclear factor 1 A-type (NF1A),
S100 calcium-binding protein B (S100β), gap junction
alpha-1 protein also known as Connexin 43 (CX43), Gluta-
mate aspartate transporter (GLAST), Glutamine synthetase
(GS) and cluster of differentiation protein 44 (CD44). As
examples on how these labeled astrocytes can be used, we
assessed secretion of pro-inflammatory mediators in enriched
astrocyte cultures treated with fetal bovine serum (FBS) or
IL-1β, and uptake and degradation of pathogenic proteins in
non-purified astrocyte cultures, the latter substantiating the
usefulness of our models for the tracking of pathogenic labeled
proteins specifically in astrocytes. Finally, we demonstrate
that our protocol for generating fluorescence-based ESC
reporter lines is applicable to iPSCs. Both robustness and
easiness of our method for generating hPSC reporter lines by
transgenesis should facilitate the generation of many more
cellular models for studies where homogeneous or fluores-
cently labeled neural cell populations are necessary.
Experimental procedures
Maintenance of human ESC and iPSC lines
Human embryonic stem cell line H13 was obtained from the
Harvard Stem Cell Institute; the generation and character-
ization of the human induced pluripotent stem cell line
NAS2 is described elsewhere (Devine et al., 2011). Human
ESCs and iPSCs were expanded on irradiated CF1 MEFs
(GlobalStem), in WiCell medium containing advanced DMEM/
F12 (Life technologies), 10% KnockOut Serum Replacement
(Life technologies), 2 mM L-glutamine (Life technologies),
1% non-essential amino acids (Millipore) and 50 μM
β-mercaptoethanol (Sigma-Aldrich), supplemented with
20 ng/ml FGF2 (from Preprotech or Life Technologies). At
thaw, in order to increase the yield of recovery of the
colonies, 20 μM of the Rho-Kinase inhibitor Y-27632 (Abcam)
was added to the medium. Medium was changed daily, and
colonies were regularly passaged using dispase (Life Tech-
nologies). Cells were kept at 37 °C under 5% CO2. The use of
human ESCs and iPSCs is in line with Lund University and
national guidelines.
cDNA construct
The pBluescript-GfaABC1D was a gift from Prof. Michael
Brenner (University of Alabama-Birmingham, USA). The
construct encodes a 681 bp fragment of the human GFAP
promoter that is sufficient to result in selective expression in
murine astrocytes throughout the CNS (Lee et al., 2008). The
full sequence of the fragment is provided in supplementary
Fig. 1. The PGK::Neo-Hb9::GFP plasmid was a gift from Prof.
Hynek Wichterle (Columbia University of New York, USA),
and was previously used to generate a hESC line reporting on
motor neurons (Di Giorgio et al., 2008). The GFAABC1D
promoter fragment was inserted in place of the Hb9 promoter
using Sal1 and Asc1 restriction sites. Then, the tRFP was
inserted in place of the GFP using Asc1 and NheI restriction
sites. The PGK::Neo-GFAABC1D::tRFP construct was checked by
restriction and sequencing.Generation of human ESC and iPS cell reporter lines
Nucleofection, selection and pre-screening were performed
as follows: briefly, colonies of each single cell line (H13 and
NAS2) were dissociated into single cell cultures, concentrat-
ed and electroporated (AMAXA, B-016 program) with the
linearized vector (linearized using Not1 single restriction
site). Nucleofected cells were seeded and grown on a
monolayer of irradiated CF6NeoR MEFs (Globalstem) in
WiCell medium supplemented with 20 μM Y-27632 and
20 ng/ml FGF2. Once colonies were formed, selection was
applied by adding increasing concentrations of G418 (Life
Technologies) to the medium. Every 3 days, G418 concen-
trations were increased two-fold, to a final concentration of
400 μg/ml. Resistant colonies were picked and expanded
separately for storage and pre-screening. Here, cultures
were considered positive once RFP expression was observed.
Pre-screening was carried out using the midbrain differen-
tiation protocol described hereafter.Differentiation of human ESCs and iPSCs into CNS
regionalized astrocytes
One day prior to start of differentiation, human ESC and
iPSC colonies (wild-type or transgenic) were harvested
using dispase, and seeded into ultra-low attachment plates
(Corning) in Wicell medium supplemented with FGF2 and
Y-27632. The day after (day 0), patterning of newly formed
embryoid bodies (EBs) toward midbrain (floor-plate) or
spinal cord fate was initiated. For patterning into mid-
brain identity, medium was changed to advanced DMEM/
F12:Neurobasal (1:1) supplemented with 2% (v/v) B27 minus
vitamin A and 1% (v/v) N2, 2 mM L-glutamine, 1% non-
essential amino acids and penicillin/streptomycin (all from
Life Technologies). Midbrain identity was directed by
supplementing media with 0.1 μM LDN-193189 (from D0 to
D8; Stemgent), 10 μM SB-431542 (from D0 to D6; Sigma-
Aldrich), 200 ng/ml SHH-C25II N-terminus (from D0 to D12;
Life Technologies), 0.8 μM CHIR-99021 (from D0 to D12;
Stemgent) and 1 μM of smoothened agonist (SAG; from D2 to
D12; Millipore), as previously described (Kirkeby et al.,
2012a). Medium was changed every other day. Patterning
toward spinal cord lineage was started in WiCell media (from
D0 to D4) with a gradual shift (from D4 to D6) to glial
induction media (GIM) composed of advanced DMEM/F12
with 2% (v/v) B27 plus vitamin A, 2 mM L-glutamine, 1% (v/v)
non-essential amino acids and penicillin/streptomycin.
Media were supplemented with 0.1 μM LDN-193189 (from
D0 to D6) and 10 μM SB-431542 (from D0 to D6), 1 μM of
retinoic acid (RA; from D2 to D12, Sigma-Aldrich), 200 ng/ml
SHH-C25II N-terminus (from D6 to D12), 10 ng/ml BDNF
(from D6 to D12, Life Technologies), 0.4 μg/ml ascorbic acid
(from D6 to D12, Sigma-Aldrich), as recently described
(Lamas et al., 2014). For both midbrain and spinal pat-
terning, medium was changed every other day. From day 12
of differentiation, free-floating cultures containing region-
alized EBs were grown in GIM supplemented with 20 ng/ml
FGF2 and 100 ng/ml EGF (Preprotech; Nelson et al., 2008).
EBs were cultured under these conditions until day 45 and
medium was changed twice a week. At day 45, EBs were
collected and dissociated using Accutase (Life Technologies).
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(Sigma-Aldrich) and 5 μg/ml laminin (Life Technologies). Cells
were cultured in GIM supplemented with 1% (v/v) FBS (Life
Technologies) until day 130. When confluent, cultures were
passaged using trypsin-EDTA (Life Technologies).
Flow cytometry analysis and FACS
Cells were dissociated using trypsin and re-suspended in
magnesium/calcium-free PBS supplemented with 10% FBS
(v/v). Samples were analyzed and sorted using a BD FACSAria
III (BD Biosciences) with FACSDiva v8.0 software (BD Biosci-
ences), at the MultiPark Cellomics and Flow Cytometry Core
technical platform, at Lund University. The cytometer was set
up using a 100 μm nozzle at standard pressure of 20 psi and a
frequency of 30.0 kHz and was calibrated daily using BD
FACSDiva Cytometer Setup and Tracking (CS&T) software and
CS&T Research Beads (BD Biosciences). For sorting, drop delay
was optimized with Accudrop beads (BD Biosciences) to N99%
of beads sorted in “fine tune” sort mode. Cells were sorted at
sort mode 0-32-0 (yield mask 0, purity mask 32, phase mask
0). 7-Aminoactinomycin D (7AAD) was excited by the blue
laser (488 nm/20 mW) and emission was detected through a
695/40 bandpass (BP) filter. RFP was excited by the yellow/
green laser (561 nm/50 mW); emission at 610/20 BP. PMT
were set using unstained and fully stained cells and emission
was detected as the area of fluorescence intensity. In short,
the strategy for gating was separating out 1) single cells based
on FSC-W/FSC-A and SSC-W/SSC-A (Supplementary Fig. 2A
and B), 2) live and dead cells based on uptake of 7AAD
(Supplementary Fig. 2C), and 3) RFP positive cells compared
to non-reporter expressing astrocytes (Supplementary Fig.
2D). Compensation was set up using single-positive cells for
RFP and 7AAD. Each analysis was based on 10,000 to 20,000
events. Samples were sorted at 4 °C directly into GIM medium
supplemented with 1% (v/v) FBS. Re-analysis of test-samples
showed sort purity greater than 97% and dead cells b5% of
non-enriched populations. Sorted cells were then seeded onto
poly-ornithine/laminin-coated plates.
Immunocytochemistry
Cells were fixed using 4% paraformaldehyde (Sigma-aldrich)
for 30 min at room temperature and incubated for 1 h at
room temperature (RT) with blocking buffer containing 0.1%
Triton-X (Sigma-Aldrich) and 10% donkey serum (Millipore) in
PBS. Subsequently, cells were incubated with primary
antibodies diluted in blocking buffer overnight at 4 °C.
Cultures were then washed with PBS and incubated with
secondary antibodies in PBS 0.1% Triton-X for 1 h at RT.
Primary antibodies used in this study were: polyclonal
anti-GFAP (1:5000; Z033401-2, DAKO), monoclonal anti-GFAP
(1:100; G3893, Sigma-Aldrich), monoclonal anti-HOXB4 (1:80;
I12 anti-Hoxb4, DSHB), polyclonal anti-OTX2 (1:500; AF1979,
R&D), polyclonal anti-GLAST (1:200; AF6048, R&D), monoclo-
nal anti-Glutamine synthetase (1:1000; MAB302, clone GS-6,
Millipore), monoclonal anti-CD44-FITC (1:30; 555478, clone
G44-26, BD-Bioscience), polyclonal anti-LMX1A (1:500; 50.5G5,
DSHB), monoclonal anti-FOXA2 (1:100; sc-6554, Santa Cruz
Biotechnology), polyclonal anti-NF1A (1:100; 39036, Active
Motif), monoclonal anti-S100β (1:500; S2532, Sigma-Aldrich),monoclonal anti-CX43 (1:500; C6219, Sigma-Aldrich), polyclon-
al anti-tRFP (1:5000; AB234, Evrogen). For fluorescence micro-
scopy analysis, secondary antibodies conjugated to Alexa-488,
555 or 647 (1:400; Donkey, Life Technologies) were used.
RT-qPCR
Cultures of progenitors aged 12 DIV were treated with Trizol
for RNA extraction, according to standard procedures. Samples
were analyzed using the Bio-Rad CFX-96 apparatus, using a
protocol customized according to the instructions of the
SsoFast™ EvaGreen® Supermix (Bio-Rad). Relative quantifica-
tion was applied using the GAPDH as reference gene. All
RT-qPCR reagents were purchased from Life Technologies.
The following primers were used: EN1, GTGTCTGCCCACCTCT
TCTC (For) and GCAGTCTGTGGGGTCGTATT (Rev); FOXA2, CC
GTTCTCCATCAACAACCT (For) and GGGGTAGTGCATCACCTGTT
(Rev); GAPDH, GAAATCCCATCACCATCTTCCAGG (For) and
GAGCCCCAGCCTTCTCCATG (Rev); HOXB4, ACACCCGCTAACAA
ATGAGG (For) and GCACGAAAGATGAGGGAGAG (Rev); LMX1A,
AGAGCTCGCCTACCAGGTC (For) and GAAGGAGGCCGAGGTGTC
(Rev); OTX2, GAAGCTCCATATCCCTGGGTGGAAAG (For) and
CCATGACCTATACTCAGGCTTCAGG (Rev); PAX6, GGCAACCTAC
GCAAGATGGC (For) and TGAGGGCTGTGTCTGTTCGG (Rev).
Microscopy and quantification
Cultures were imaged under an inverted microscope (Olym-
pus IX73 equipped with Hamamatsu C11440 Orcaflash 2.8
camera). Whole well images were acquired using the plate
Runner HD from Trophos (at a resolution of 2046 × 2046
pixels). Automated quantitative image analysis of fluores-
cent and stained astrocyte cultures was performed using the
MetaMorph Software V7.8.6.0 (Molecular Devices). Quanti-
tative analysis of stained hPSC-derived astrocyte cultures
was performed using the Multi-Wavelength Cell Scoring
application. For a specific marker, positive cells were
selectively identified as having clear signal intensity above
local background. Intensity thresholds were set blinded to
sample identity. In a given experiment the same parameters
were used in all images analyzed, for all conditions.
Parameters were only minimally adjusted across different
experiments.
IL-6 ELISA and protein array
FACS-purified astrocytes were seeded in GIM medium
containing 1% (v/v) FBS 2 days before the experiment. On
the day of the experiment cells were washed twice with
non-supplemented GIM and subsequently treated with either
GIM plus 1% (v/v) FBS or GIM pus 10 ng/ml IL-1β (R&D). On
day 7, media was harvested for protein array and ELISA.
Briefly, for ELISA analysis samples were diluted 1:10 and
applied to an IL-6 ELISA assay (KHC0061, Life Technologies),
according to manufacturer's guidelines. Absorbance at 450 nm
was measured by spectrophotometry. Human cytokine array
panel A (ARY005, R&D Systems) was used according to
manufacturer's guidelines. Intensities were measured using
ChemiDoc software (Bio-Rad) and were normalized to mean
intensities of reference spots.
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astrocyte cultures
Human alpha-synuclein (S 1001 2, rPeptide) was Atto-labeled
according to the manufacturer protocol (#38371 Sigma). Fibrils
were generated by mixing 100 μg of human alpha-synuclein
and 21 μg of Atto-labeled human alpha-synuclein in a total
volume of 165 μl 50 mM Tris, 250 mM NaCl, pH 7.5 solution.
This solution was incubated for 7 days at 37 °C (in the dark)
using the following cycle: Shaking (300 rpm) 3 days, left
overnight without shaking, shaking for 4 additional days.
Preparations were then evaluated by electron microscopy to
ensure that fibrillation had taken place (data not shown).
Before use, fibrils were sonicated twice 30 s at 40% amplitude
with a sonicator (QSonica, 125A-220). Cultures were then
incubated with 0.7 μM of either monomers or fibrils for the
indicated periods.
Results
Astrocyte differentiation varies significantly between
midbrain, but not spinal cord, cultures
Our overall aim was to generate fluorescence-based PSC
reporter lines for the isolation of and reporting on human
astrocytes generated from regionally distinct neural progen-
itors. Since human ESC are most commonly utilized to
generate reporter lines (Di Giorgio et al., 2008; Fischer et
al., 2010; Liu et al., 2011; Placantonakis et al., 2009) we
used the human ESC line, HuES13 (H13) for generating
our astrocyte reporter line. At first, we developed neural
induction protocols that specify neuroepithelial cells toward
ventral spinal cord or ventral midbrain floor-plate identities.
For the rapid generation of regionalized progenitors, human
ESCs were routinely expanded as adherent colonies on
irradiated MEFs, and dissociated and seeded onto Matrigel-
coated plates forming monolayer cultures. When confluent,
cultures were neuralized by dual inhibition of SMAD signaling
using LDN and SB (Chambers et al., 2009), and regionalized
toward a caudal ventral fate or midbrain ventral fate using
RA and SHH or CHIR and SHH and SAG, respectively (Fig. 1A),
as previously described (Kirkeby et al., 2012b; Krencik et al.,
2011; Kriks et al., 2011; Roybon et al., 2013). We monitored
the appearance of regional identity markers 12 days after
initial treatment with the patterning factors. Neural pro-
genitors directed toward a caudal ventral fate expressed
HOXB4 and FOXA2, while those directed toward a midbrain
ventral fate expressed FOXA2 and lacked HOXB4. Notably,
midbrain neural progenitors co-expressed FOXA2 and LMX1A
(Fig. 1B and C). Because we employed low concentrations of
SHH (200 ng/ml), few LMX1A-expressing cells could be
detected in spinal cord cultures. These LMX1A positive cells
however were negative for FOXA2, and were representative
of a more dorsally located population in the spinal cord
(Chizhikov and Millen, 2004). The majority of the cells
expressing FOXA2 were reminiscent of populations located
more ventrally (Lek et al., 2010; Ribes et al., 2010). We
confirmed the regional identity of the neural progenitors by
RT-qPCR for the markers OTX2, EN1, LMX1A, FOXA2, HOXB4
and PAX6 (Fig. 1E). Thus, treatment with LDN, SB, RA and
SHH (hereafter referred to as the spinal protocol) mainlyresulted in the production of FOXA2+/PAX6+/HOXB4+ neural
progenitors, while treatment with LDN, SB, CHIR and SHH
(hereafter referred to as the midbrain protocol) resulted
in cultures containing OTX2+ midbrain floor plate neural
progenitors co-expressing FOXA2 and LMX1A.
We next expanded the neural progenitors in medium
containing FGF2 and EGF to generate cultures enriched in
glial progenitors (Krencik et al., 2011), which we differen-
tiated into astrocytes by withdrawal of the mitogens, and
adding FBS (Roybon et al., 2013) (Fig. 1A). Three months
after the initiation of the spinal cord and midbrain dif-
ferentiations, we could still identify the presence of regional
identity markers HOXB4 and OTX2, in spinal cord and mid-
brain cultures, respectively (Fig. 1D). Notably, we observed
a robust expression of GFAP in spinal cord cultures (Fig. 1F).
This was however not the case for midbrain cultures
(Fig. 1G). Out of 10 midbrain cultures differentiated from
ESC stage, half gave rise to large amounts of GFAP-
expressing cells, while all spinal cord cultures robustly
generated GFAP-expressing cells (hereafter referred to as
spinal cord astrocytes). The variability in GFAP-expressing
astrocytes generated from human ESC-derived midbrain
progenitors (hereafter referred to as midbrain astrocytes)
may indicate that the purity of neural progenitors in
midbrain cultures is not always ascertained, or that the
degree of maturity of midbrain astrocytes in cultures may
differ between preparations. This result emphasized the
need for generating cellular models that would enable
identification and/or purification of astrocytes for several
purposes.Methodology for generating stable transgenic hESC
lines reporting on astrocyte differentiation
Several methods exist to generate fluorescence-based reporter
cell lines. The most commonly employed are BAC transgenesis
(Placantonakis et al., 2009; Rostovskaya et al., 2012) and gene
targeting (Fischer et al., 2010; Liu et al., 2011), but those
require large plasmids which often break during electropora-
tion and specific molecular tools not always accessible in every
laboratory, respectively. Here, we generated stable human
ESC lines by electroporation of a plasmid containing a
neomycin resistance gene and a red fluorescent protein
gene which are driven by the phosphoglycerate kinase-1
promoter and the ABC1D region of the human GFAP promoter,
respectively (Fig. 2A and Supplementary Fig. 1; see Experi-
mental procedures). Colonies surviving geneticin (G418)
selection (n = 39) were harvested and individually expanded
for differentiation and cryopreservation (Fig. 2B). Although the
selected clones carried the resistance cassette, it is possible
that the reporter cassette, despite its small size, was
damaged during electroporation. Therefore, we performed a
second selection by pre-screening the resistant clones for
reporter expression. Since variability was observed in the
amount of GFAP-expressing cells generated using the midbrain
protocol, but not the spinal protocol, we decided to
differentiate the clones using the midbrain protocol at first,
to ensure the selection of TagRFP-expressing clones, in
advance of extended characterization and validation using
the spinal cord protocol. We differentiated the 39 neomycin-
resistant clones into midbrain astrocytes as adherent cultures
208 S. Holmqvist et al.in a 96 well plate format and observed for reporter expression.
When most of the cultures reached confluence, all differenti-
ating clones were simultaneously passaged. After 70 days
of in vitro culture, natural fluorescence-based reporterexpression was assessed. Twelve of the 39 clones showed
reporter expression and immunohistochemistry revealed co-
localization of TagRFP with GFAP in 11 clones (Fig. 2C). Thus,
these two steps of selection allowed identification of 11
Figure 2 Generation of astrocyte reporter lines from hESC. A. Schematic representation of the construct generated and used to
generate astrocyte pluripotent stem cell reporter lines. B. Strategy employed for generating astrocyte reporter lines from human
embryonic stem cells. Nucleofection of reporter construct into PSCs followed by selection for resistant clones using geneticin. After
expansion of the clones pre-screening was preformed for selection of clones co-expressing GFAP and GFAABC1D::TagRFP. C. Detection of
reporter expression in cultures aged 70 DIV, during the pre-selection phase. Images show abundance of GFAP/GFAABC1D::TagRFP-cells.
Scale bar represents 20 μm. D. Summary of the number of clones obtained during the different selection steps.
209Human astrocyte PSC reporter linesG418-resistant GFAABC1D::TagRFP-expressing clones (Fig. 2D);
these were processed further to assess long-term reporter
expression in astrocyte cultures.Characterization of reporter expression in midbrain
progenitor-derived astrocytes
We next characterized long-term reporter expression
through a time course study of 130 days in vitro (DIV).
Cultures were grown side-by-side, as free-floating embryoid
bodies (EBs), in a 12 well-plate format (see experimentalFigure 1 Differentiation of hESC-derived ventral spinal cord and v
Schematic representation of the protocols used to differentiate hES
subsequent differentiation into astrocytes. B. Overview of the locat
regions of the neural tube. C. Immunocytochemistry performed at
FOXA2, and absence of HOXB4 in ventral midbrain progenitors. Spin
and FOXA2. Scale bar represents 50 μm. Images are representativ
performed at day 70 of differentiation shows abundance of regional
OTX2 and HOXB4, respectively. Images are representative of n = 2 d
shows up-regulation of regional identity markers in cultures diffe
lineages. Mean ± s.e.m.; n = 3. F and G. Images of whole culture
differentiation reveals variability in the amount of GFAP-expres
side-by-side from pluripotent stem cell stage. Scale bar representsprocedures). From day 45 onward, cultures were grown on
adherent substrate in medium containing FBS (1% v/v) to
allow differentiation of midbrain neural precursors into
astrocytes. At this stage of differentiation, attached cultures
were passaged weekly and cells were harvested for analysis of
reporter expression using FACS at 70, 90, 110 and 130 days of
differentiation in vitro (Fig. 3A and Supplementary Fig. 2). We
could not detect GFAABC1D::TagRFP in EBs (data not shown) and
cultures of midbrain progenitors aged 45 DIV (Fig. 3B). This was
not the case in older cultures where differences were clearly
identified between clones, in term of intensity of reporter
expression and number of cells expressing GFAABC1D::TagRFPentral midbrain progenitors into GFAP-expressing astrocytes. A.
Cs into ventral spinal cord and ventral midbrain progenitors and
ion of and protein expression in spinal and midbrain floor-plate
day 12 of differentiation reveals co-expression of LMX1A and
al cord progenitors express HOXB4 and do not co-express LMX1A
e of more than five differentiations. D. Immunocytochemistry
ly specified cells in midbrain and spinal cord cultures expressing
ifferentiations. Scale bar represents 20 μm. E. RT-qPCR analysis
rentiated toward midbrain floor plate and ventral spinal cord
wells stained for GFAP (green) and DAPI (blue) at day 90 of
sing cells produced for 10 midbrain differentiations started
1 mm.
Figure 3 Characterization of reporter expression in midbrain progenitor-derived astrocytes, in vitro. A. Schematic representation of
the experimental approach carried out to study reporter expression. Cultures were grown on adherent substrate from day 45 onward,
and passaged at confluency. Lower black arrows represent the time points for flow cytometry analysis. Upper black arrow represents
FACS purification of cultures for long-term characterization. B. Absence of reporter expression in adherent cultures at 45 DIV. Cells
express the reporter after 90 DIV. Inset show bright-field images of cultures devoid of GFABC1D::TagRFP-expressing cells. Scale bar
represents 20 μm. C. Flow cytometry plots represent live single cells analyzed for reporter expression, at day 110 of differentiation,
and reveal differences in reporter intensity and number of GFABC1D::TagRFP-expressing cells. D. Graphs represent time course study
of the percent of GFAABC1D::TagRFP positive cells out of live single cells, measured by flow cytometry. Missing values are the result of
insufficient cells for FACS analysis due to slow division rate (C22 and C39, day 70), or loss of cells due to bacterial infections (C39, day
130). Mean ± s.e.m.; n = 3 differentiations.
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Figure 4 Long-term characterization of FACS-purified cultures, using the midbrain astrocyte protocol. A. Reporter and GFAP
expression assessed for C9, C28 and C32 in purified cultures, at 130 DIV. Bar diagrams represent the percentage of GFAABC1D::TagRFP
positive cells (out of living cells; measured by FACS) and the percentage of GFAP/GFAABC1D::TagRFP
bright double positive cells (out of
DAPI stained cells). Mean ± s.e.m.; n = 3 separate differentiations. B. Maintenance of reporter expression (red) in purified C32
midbrain cultures coincides with GFAP (green) expression. Scale bar represents 20 μm. C. Panel of canonical markers expressed by
midbrain astrocyte 40 days post-enrichment by FACS; at this time point, cultures are 130 DIV. Images show homogenous cultures of
astrocytes co-expressing TagRFP and canonical markers NF1A, CX43, GLAST, GS, S100β and CD44. Nuclei are indicated with DAPI
staining. Scale bar in main panel represents 20 μm and in insets 5 μm (bottom right panels). D. Flow cytometry analysis of cultures
stained for S100β or CD44 confirming the immunocytochemistry data. FACS plots show number of FITC-positive cells above threshold.
E. Flow cytometry analysis of CD44 stained astrocytes. Left plot shows analysis of unstained astrocytes generated from a
non-astrocyte report line (=non labeled control sample). Right plot shows TagRFP-expressing astrocytes co-expressing CD44 (shown
for clone 32).
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212 S. Holmqvist et al.(Fig. 3B and C). Notably, FACS analysis of clones revealed that
at 70 DIV, less than 25% of live single cells expressed
GFAABC1D::TagRFP (Fig. 3D).Figure 5 Long-term characterization of reporter expression in hESC
into astrocytes. A. Absence and presence of reporter expression in
image confirm the presence of cells in cultures aged 45 DIV. Scale b
cells analyzed for reporter expression, at day 110 of differentiation
positive cells out of live single cells, over time (measured by flow
Purified C32 spinal cord astrocytes grown for 40 additional DIV main
represents 20 μm. Nuclei are stained with DAPI (blue). D. Bar diagram
FACS) and number of GFAP/TagRFP double positive cells in culture
cells. E. Panel of canonical markers expressed by spinal cord
homogenous, and composed of TagRFP astrocytes co-expressing can
are indicated with DAPI staining (blue). Scale bar in main panel reprWe next analyzed the degree of enrichment in GFA-
ABC1D::TagRFP-expressing cells after purification by FACS,
and reporter expression after subsequent culture for atransgenic clone C32, during differentiation of spinal progenitors
spinal cultures at 45 DIV and 90 DIV, respectively. Bright-field
ar represents 20 μm. B. FACS plot (on the left) shows live single
. The graph shows increase in the number of GFAABC1D::TagRFP
cytometry). Mean ± s.e.m.; n = 3 separate differentiations. C.
tain tagRFP expression and co-express GFAP (green). Scale bar
show the total number of TagRFP-expressing cells (measured by
s purified at day 90, grown for 40 additional days, out of single
astrocyte in cultures, 40 days post-enrichment. Cultures are
onical markers NF1A, CX43, GLAST, GS, S100β and CD44. Nuclei
esent 20 μm and in insets 5 μm.
213Human astrocyte PSC reporter linesperiod of 40 additional DIV, the latter to assess possible loss of
reporter expression. For this analysis, we chose to character-
ize three clones: C9 and C32 which displayed strong reporter
intensity measured by FACS, and clone 28 which gave rise to
the greatest number of GFAABC1D::TagRFP-expressing cells,
over time (Fig. 3D). Cultures FACS-purified on day 90, and
grown for 3 additional days, showed a nearly complete
enrichment in reporter-expressing cells (Supplementary Fig.
3A). This was however not observed in populations that
were sorted after 90 DIV and subsequently cultured for 40
additional DIV. At that time point, assessment of reporter
expression by FACS revealed a decrease in the number of
GFAABC1D::TagRFP-expressing cells in purified culture for
C9, whereas little change was observed in purified cultures
for C28 and C32 (Fig. 4A). As the intensity of reporter
expression varied between the clones, we next analyzed
the overlap between GFAP and GFAABC1D::TagRFP. We
performed quantitative analysis of bright fluorescent reporter
(GFAABC1D::TagRFPbright)-expressing cells in cultures stained
for GFAP and DAPI. The percentage of cells co-expressing
GFAP and GFAABC1D::TagRFPbright for purified cultures of
C32 reached ~80% of the GFAP-expressing cells. This how-
ever was not the case for C9 and C28 since the majority of
the cells variably and weakly expressed the reporter. Thus,
C32 appeared to be the most robust candidate clone suitable
for reporting on midbrain astrocyte differentiation based
on the co-expression of GFAP and GFAABC1D::TagRFPbright
(Fig. 4B).
The astrocyte identity of reporter-based purified C32
cells had yet to be validated using additional markers. We
therefore performed immunocytochemistry on 130 DIV old
C32 purified cultures, for the astrocyte markers NF1A, CX43,
GLAST, GS, S100β and CD44 markers. While nearly all cells
present in purified cultures at 130 DIV expressed the
astrocyte markers (Fig. 4C), none stained positive for the
neuronal and oligodendroglial markers neurofilament and
CNPase, respectively (data not shown). FACS analysis of
cultures stained for S100β or CD44 confirmed our immuno-
cytochemistry data (Fig. 4D and E).Characterization of reporter expression in C32
astrocyte cultures generated from hESC-derived
spinal cord progenitors
Since we aimed to generate a stable transgenic hESC line
reporting on astrocytes generated from midbrain and spinal
progenitors from a single line, we repeated our analysis now
on C32 astrocyte cultures generated using the spinal cord
protocol. We differentiated clone C32 from hESC stage, as
described above. As for midbrain cultures, spinal cultures
contained cells with bright reporter expression (Fig. 5A
and B) with a high degree of co-expression of GFAP and
GFAABC1D::TagRFPbright, 3 days after FACS (Supplementary
Fig. 3B). Enrichment by means of FACS at day 90 and
subsequent culture for 40 additional days resulted in
homogenous cultures composed of GFAP/GFAABC1D::TagRFP
expressing cells (Fig. 5C and D). At 130 DIV, nearly all
purified cells present in culture expressed the astrocyte
markers NF1A, CX43, GLAST, GS, S100β and CD44 (Fig. 5E).
Thus, clone C32 was selected as potential hESC line for
the isolation of and reporting on astrocytes differentiatedfrom midbrain and ventral spinal cord progenitors generated
from a single hESC line.Human ESC midbrain and spinal cord
progenitor-derived GFAABC1D::TagRFP-expressing
astrocytes are suitable for inflammatory profiling
and protein uptake assays
The relevance of our cell models was tested using two
distinct paradigms. The first consist of measuring the
secretion of pro-inflammatory cytokines and chemokines
from GFAP-expressing astrocytes only; it requires pure
population of astrocytes in order to reach informative
data, which could now be obtained by purifying astrocytes
by FACS. The second assay consists of visualizing the uptake
of labeled proteins, potentially pathogenic, into astrocytes;
this assay requires that astrocytes are labeled and does not
require homogenous cultures.
Purified midbrain and spinal cord astrocytes generated
from C32 were treated for 7 days with FBS (1% v/v) or IL-1β
(10 ng/ml; no FBS). IL-1β was shown to induce reactivity
and expression and release of pro-inflammatory factors of
hPSC-derived spinal cord astrocytes, which can be moni-
tored by assessing the upregulation of the chemokine
RANTES and the secretion of the cytokine IL-6 (Roybon et
al., 2013). However, this had not been tested for astrocytes
generated from hESC-derived ventral midbrain progenitors.
Therefore, we performed a qualitative analysis using protein
array, where we compared the changes in cytokine and
chemokine secretions from FACS-purified astrocytes aged
130 DIV differentiated from midbrain and spinal cord neural
progenitors from C32, following treatment with IL-1β
(Fig. 6A). Protein array analysis showed that IL-6 was not
released in FBS treated samples, in contrast to cultures
treated with IL-1β, which is concordant with previous
finding (Roybon et al., 2013). Similar levels of IL-6 secreted
by the astrocytes were detected in both spinal and midbrain
cultures; this lack of difference in IL-6 secretion between
midbrain and spinal cord astrocytes was further confirmed
by ELISA (data not shown).
Several other cytokines and chemokines were also newly
secreted upon IL-1β treatment for both midbrain and spinal
cord cultures (Fig. 6A). Interestingly, GROα (also known as
CXCL1) and IL-8 were already present in midbrain cultures
treated with FBS, while they were newly secreted in spinal
cord cultures treated with IL-1β. In general, a tendency
towards increasing secretion of similar chemokines and cyto-
kines in both IL-1β-treated midbrain and spinal cord cultures
was observed. The only drastic decline observed between
treatments concerned CCL2 (also known as MCP-1), whose
secretion was decreased following IL-1β treatment in both
midbrain and spinal cord cultures (Fig. 6A). This finding is in
line with recent work showing a down regulation of this
protein in cultures composed of primary inflammatory human
astrocytes (Choi et al., 2014), and whose absence exacerbates
the release of several pro-inflammatory cytokines including
IL-6, G-CSF, IL-1β and CXCL1, indicating a negative regulatory
role of CCL2 in neuroinflammation (Semple et al., 2010). In
general, no dramatic differences in cytokine and chemokine
secretions were observed between midbrain and spinal cord
cultures treated with IL-1β.
Figure 6 Examples of read-out assays using GFAABC1D::TagRFP astrocytes. A. Overview of the cytokines and chemokines expressed
following treatment with FBS and IL-1β, of purified midbrain and spinal cord astrocytes aged 130 DIV. B. Upper panel images show
cellular localization of αSYN in 90 DIV unpurified midbrain astrocyte cultures treated for 3 h with ATTO488-labeled αSYN species.
Lower panel images show cellular localization of aSYN in cultures treated with ATTO488-labeled aSYN species, at 7 DIV. White
arrowheads pinpoint DNA fragmentation. Scale bar represents 10 μm.
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215Human astrocyte PSC reporter linesA large body of evidence suggests that glia play an
important role in synucleinopathies through the accumula-
tion of pathogenic proteins such as α-synuclein. Since rodent
primary glia (astrocytes and microglia) can internalize
α-synuclein in vitro (Lee et al., 2010; Zhang et al., 2005),
and α-synuclein inclusion bodies were described in people
with PD (Wakabayashi et al., 2000), we attempted to
demonstrate additional relevance of our models, by inves-
tigating whether labeled α-synuclein protein could be
tracked in GFAABC1D::TagRFP-expressing human astrocytes
derived from midbrain progenitors. This test would further
confirm the functionality of our astrocytes by being capable
of taking up proteins. For this aim, we treated unpurified
cultures generated from the clone C32 and aged 90 DIV, with
ATTO488-labeled α-synuclein species. Three hours treat-
ment sufficed to observe ATTO488-labeled α-synuclein
monomers in vesicular-like structures in all cells. In contrast,
fibril species seemed to accumulate at the cellular membrane
(Fig. 6B), as recently observed by Reyes and coworkers, in an
OLN-93 cell line model for oligodendrocytes treated with
α-synuclein fibrils (Reyes et al., 2014). After 7 days of
treatment, both monomers and fibrils were clearly observed
in vesicular-like structures, demonstrating ongoing clearance
of α-synuclein species by human astrocytes (Fig. 6C). Inter-
estingly, we identified the presence of peri-nuclear inclusions
and DNA fragmentation in GFAABC1D::TagRFP-expressing astro-
cytes, as previously described in other cellular experimental
models (Bousset et al., 2013; Lee et al., 2010).
Overall, our data show that C32 can be used to generate
homogeneous populations of functional astrocytes from
regionally defined neural progenitors, which can be used
for studies of inflammation in vitro, and to track the
dynamics of pathogenic proteins in human fluorescently
labeled astrocytes.Generation of GFAABC1D::TagRFP report line for the
reporting on astrocytes generated from human
induced pluripotent stem cell-derived midbrain and
spinal cord progenitors
Since human iPSCs are becoming an important model for
investigating human diseases in vitro (Wichterle and
Przedborski, 2010), we decided to test whether our strategy
for generating hESC lines reporting on astrocytes could
successfully be applied to hiPSCs. Similar to hESC, we
generated hiPSC lines for reporting on midbrain and spinal
cord astrocytes. We nucleofected the previously character-
ized hiPSC line, NAS2 (Devine et al., 2011), and harvested
G418-resistant clones (n = 88) which we pre-screened using
the methodology we described for the hESC clones. Out of 88
resistant clones, 14 clones showed reporter expression in
cultures differentiated for 70 DIV, and co-expressed GFAP.
These were selected and expanded for cryopreservation and
further analysis. The clones were then differentiated from
pluripotent stage using the protocols we developed to
generate spinal cord and midbrain progenitors. At day 45 of
differentiation, few cells in several clones differentiated
using the astrocyte spinal cord protocol expressed the
reporter (Fig. 7A). The number of reporter expressing cells
increased over time similar to what was observed for the
hESC clone C32 (Fig. 7B). Clone C70 was selected based uponlive imaging and FACS analysis. Reporter-expressing cells in
purified midbrain and spinal astrocyte cultures aged 130 DIV,
both expressed NF1A, S100β and CD44 (Fig. 7C and D) as well
as GLAST, GS, and CX43 (data not shown). Moreover, purified
astrocytes were functional as they secreted IL-6 upon
stimulation with IL-1β and it was possible to identify
ATTO488 labeled α-synuclein in TagRFP astrocytes (Fig. 7E),
similar to hESC-derived midbrain astrocytes. Therefore, we
concluded that our protocol for generating human PSC
reporter lines was also applicable to hiPSCs, and that the
functional assays conducted using the reporter lines were
relevant for both human ESC- and iPSC-derived astrocytes.Discussion
Human astrocytes are highly heterogeneous and little is
known about their development in the CNS. Differentiation
of human PSCs into regionalized neural progenitors, which
can be further differentiated into astrocytes, offers a new
venue of research contributing to investigations of astrocyte
development and diversity. These regionally specified astro-
cytes could be valuable models for studies of disease
mechanisms, or as therapeutic vehicles, and homogeneous
cultures of fluorescently labeled astrocytes could be an
advantage over the use of heterogeneous, non-fluorescently
labeled astrocytes for these purposes. Therefore, we
engineered human PSC lines to report on astrocytes generated
from regionally specified progenitors.
First, to enable investigation of the lines reporting on
midbrain and spinal cord astrocytes, two differentiation
protocols were developed. These rely on three different
steps where neural progenitors are generated and regional-
ized, expanded and finally differentiated into astrocytes.
The midbrain protocol led to the generation of PAX6-/EN1+/
OTX2+ midbrain floor-plate neural progenitors co-expressing
LMX1A and FOXA2, while the spinal cord protocol led to
the emergence of PAX6+/FOXA2+/HOXB4+ caudal-ventral
progenitors. Interestingly, GFAP expression largely varied
between different cultures independently differentiated
with the midbrain protocol, at day 90 of differentiation,
while GFAP expression between spinal cord cultures was
relatively similar. This difference might be attributable to
the use of retinoic acid for generating spinal cord astrocytes.
Indeed, retinoic acid is one of the most potent inducers of
neural differentiation in human ESCs (Schuldiner et al.,
2000). Moreover, protocols for generating spinal cord astro-
cytes have been more widely used, and are better optimized
than the few developed for generating midbrain astrocytes.
Thus, our new cellular models could help devise new
protocols for the robust generation of human PSC-derived
midbrain floor plate astrocytes, as well as protocols for
generating astrocytes from other brain regions (e.g. dorsal
and ventral forebrain astrocytes), provided that reporter
expression is confirmed in cortical and striatal astrocytes.
We chose to use the human GFAABC1D promoter to drive
TagRFP in human astrocytes because of its accuracy to
specifically direct reporter expression in astrocytes in several
CNS regions, at embryonic and adult stage, in rodent (Lee et
al., 2008). Interestingly, during the pre-screening stage, at
70 DIV, not all GFAP-expressing astrocytes co-expressed
GFAP::TagRFP (Fig. 2C). This demonstrated that increasing
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217Human astrocyte PSC reporter linesspecificity of reporter expression using the GFAABC1D promoter
that lacks several regulatory elements resulted in the loss of
large quantities of astrocytes, perhaps also revealing astrocyte
heterogeneity within the culture.
Interestingly, at day 45 of differentiation, no GFA-
ABC1D::TagRFP positive cells were observed in cultures of
any clones differentiated using the midbrain protocol. In
marked contrast, GFAABC1D::TagRFP positive cells were ob-
served in cultures aged 45 DIV for several clones differen-
tiated using the spinal cord protocol. Moreover, TagRFP
expression was stronger in spinal cord astrocyte cultures
than midbrain astrocytes, for the majority of the clones
tested (data not shown). These findings were common to
both hESC and hiPSC, and may reflect the dynamic ex-
pression of the promoter, in different part of the central
nervous system. Similar to our observation was that of Gu
and coworkers who showed that in wildtype mice, GFAP
expression is much stronger in the spinal cord than in the
brainstem (Gu et al., 2010). Nonetheless, even if TagRFP
expression appeared to be more prominent and more robust
in and between spinal cord clones compared to midbrain
clones, purification of TagRFP-expressing astrocytes gener-
ated using either of the protocols resulted in homogeneous
populations of astrocytes expressing canonical markers
NF1A, CX43, GLAST, GS, S100β and CD44, We also observed
morphological differences and varying staining intensity in
Reelin between spinal and midbrain astrocyte cultures (data
not shown).
In several instances (especially observed for midbrain
clones), the percentages of GFAP-expressing astrocytes and
TagRFP-expressing cells in purified cultures aged 130 DIV
were lower than the initial FACS-purified GFAABC1D::TagRFP+
astrocytes (Fig. 4A). This could be attributed to GFAP
down-regulation in maturing astrocytes (Roybon et al.,
2013). Moreover, the difference between reporter expres-
sion and endogenous GFAP can be attributed to half-lives of
intermediate filament proteins in astrocytes which are most
likely relatively short (Chiu and Goldman, 1984) compared to
stable fluorescent proteins such as TagRFP. Nevertheless,
the clones we selected (C32 for hESC and C70 for hiPSC)
showed high overlap between GFAP and TagRFP, and their
purification by FACS resulted in homogeneous cultures of
astrocytes expressing canonical astroglial markers.
Notably, astrocytes generated from the human ESC
reporter line could be used in several assays. Interestingly,
almost all cytokines and chemokines detected in the protein
array study were also detected in a recent similar studyFigure 7 Generation and characterization of GFAABC1D::TagRFP r
derived progenitors. A. Absence of reporter expression in iPSC-de
arrowheads pinpoint at). Reporter expression is detected at 90 DIV in
study showing the percent of GFAABC1D::TagRFP positive cells out of l
and spinal cord (blue) protocol, measured by flow cytometry. M
astrocytes and n = 1 for midbrain astrocytes. C. Canonical markers
generated using midbrain (upper panels) and spinal cord (lower pa
analysis of midbrain and spinal cord cultures stained for S100β and CD
days in vitro. Graphs show number of FITC positive cells above thresh
CD44 co-expressing astrocytes clone 70 midbrain (left) and spinal c
astrocytes aged 130 DIV treated with IL-1β release IL-6, measured
localization of aSYN in 90 DIV live unpurified iPSC-derived sp
ATTO488-labeled aSYN monomers. Scale bar represents 10 μm.employing human fetal astrocytes (Choi et al., 2014). In
concordance with our data, Choi and coworkers found MCP-1
secretion reduced. In contrast, while our data indicated no
change in MIF secretion between FBS and IL-1β treated
cultures, they reported that the secretion of this anti-
inflammatory cytokine decreased following a one-day treat-
ment period with two cytokines: IL-1β and TNFα. This
decrease in MIF secretion may only be detectable after short
treatment, or attributed to the presence of TNFα. Never-
theless, all other cytokines and chemokines were commonly
secreted in both studies. It is worth mentioning that our
new models have additional uses, such as the tracking of
pathogenic protein labeled with ATTO488 in astrocytes
in unpurified cultures, where astrocytes generated from
regionalized progenitors are labeled using GFAP::TagRFP.
Together, our findings indicate that the lines we generated
to report on astrocytes could be useful for future studies of
neuroinflammation and astrocyte diversity. Moreover, they
provide a new platform to study the dynamics of pathogenic
proteins aggregation or their transfer in and between living
human astrocytes.
Finally, as a proof-of-principle, we showed that the
reporter lines could also be generated using human iPSCs.
The hiPSC reporter lines differentiated with the spinal cord
and midbrain protocols generated astrocytes strongly re-
sembled those generated from hESC, as previously reported
for other hESC and hiPSC lines (Roybon et al., 2013). The
hiPSC clone C70 generated astrocytes responding to IL-1β
treatment, assessed by ELISA for IL-6 secretion, and able to
take up α-synuclein protein (Fig. 7E).
In this study, we have shown that the human GFAABC1D
promoter can be used to generate stable hPSC lines to report
on GFAP-expressing astrocytes. Furthermore, we have shown
that purification of fluorescently labeled astrocytes enables
enrichment of regionally defined GFAP+ astrocytes. These new
cellular models therefore offer an unprecedented opportunity
to investigate human astrocyte biology in a finer and easier
way, and provide a platform for the isolation of hPSC-derived
GFAP+ astrocytes for multiple purposes. Furthermore, the fact
that these were engineered to express TagRFP provides an
advantage for transplantation studies (Davies et al., 2011;
Lepore et al., 2008), especially in transgenic animal models
where specific neuronal subtypes are labeled with green-
fluorescent protein (GFP). Our cellular models will also be of
great interest for co-culture studies with GFP-labeled neu-
rons, and to follow uptake and degradation of fluorescently
labeled pathogenic proteins using live imaging. We envisioneport line for the reporting on astrocytes generated from iPSC
rived C70 midbrain, but not spinal cultures, at 45 DIV (white
the same cultures. Scale bars represent 20 μm. B. Time course
ive single cells (measured by FACS), for C70 using midbrain (red)
ean ± s.e.m.; n = 3 separate differentiations for spinal cord
S100β, CD44 and NF1A expression in astrocytes aged 130 DIV
nels) protocols. Scale bar represent 50 μm. D. Flow cytometry
44 show enrichment in purified cultures grown for 40 additional
old. E. Flow cytometry analysis confirms enrichment of TagRFP/
ord (right) cultures, 40 days post-FACS-purification. F. Purified
by ELISA (shown for C70 and another clone, C61). G. Cellular
inal cord astrocyte cultures (C70) treated for 4 days with
218 S. Holmqvist et al.that the generation of reporter lines for the isolation of
specific cell types will become a powerful tool for the
development of bio-diagnostic tools, with focus on personal
disparities in health and disease. Moreover, our strategy could
be adjusted to include Cre-lox flanking sites, enabling excision
of reporter cassette, for transplantation of pure non-labeled
human astocytes in the brain.
Acknowledgments
We thank M. Brenner and H. Wichterle who generously provided the
GFAABC1D promoter and the TagRFP-PGK::Neo vector, respectively.
We thank R. Sattler and F. Casagrande for the critical
reading of the manuscript.
This work was supported by the Strong Research Environ-
ment MultiPark (multidisciplinary research on Parkinson's
disease at Lund University), and grants to L.R. from the
following foundations: The Swedish Parkinson Foundation
(Parkinsonfonden), Holger Crafoord Foundation, Åke Wibergs
Foundation, Magnus Bergvalls Foundation, Greta och Johan
Kocks Foundation, and donations for science, medicine and
technology at Fysiografen in Lund. L.R. is a young investigator
supported by the Strong Research Environment MultiPark at
Lund University, and partner of the Brainstem, Stem Cell
Center for Excellence in Neurology funded by the Innovation
fund Denmark.
S.H. and M.B. performed experiments and analysis. M.D.
assisted with qPCR and M.D. and A.H. assisted with FACS.
A.G.D. generated the GFAABC1D::TagRFP-PGK::Neo con-
struct. M.J.D., T.K. and K.F. provided reagents and input
on experiments. S.H, M.B. and L.R. conceived the experi-
ments and wrote the manuscript. All authors gave input on
the manuscript and approved its final version.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.05.014.
References
Anderson, M.A., Ao, Y., Sofroniew, M.V., 2014. Heterogeneity of
reactive astrocytes. Neurosci. Lett. 565, 23–29.
Attwell, D., Buchan, A.M., Charpak, S., Lauritzen, M., Macvicar,
B.A., Newman, E.A., 2010. Glial and neuronal control of brain
blood flow. Nature 468, 232–243.
Bachoo, R.M., Kim, R.S., Ligon, K.L., Maher, E.A., Brennan, C.,
Billings, N., Chan, S., Li, C., Rowitch, D.H., Wong, W.H., et al.,
2004. Molecular diversity of astrocytes with implications for
neurological disorders. Proc. Natl. Acad. Sci. U. S. A. 101,
8384–8389.
Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P.H.,
Habenstein, B., Madiona, K., Olieric, V., Bockmann, A., Meier,
B.H., et al., 2013. Structural and functional characterization of
two alpha-synuclein strains. Nat. Commun. 4, 2575.
Brenner, M., 1994. Structure and transcriptional regulation of the
GFAP gene. Brain Pathol. 4, 245–257.
Chaboub, L.S., Deneen, B., 2012. Developmental origins of
astrocyte heterogeneity: the final frontier of CNS development.
Dev. Neurosci. 34, 379–388.
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M.,
Sadelain, M., Studer, L., 2009. Highly efficient neural conversionof human ES and iPS cells by dual inhibition of SMAD signaling.
Nat. Biotechnol. 27, 275–280.
Chao, C.C., Hu, S., Sheng, W.S., Bu, D., Bukrinsky, M.I., Peterson,
P.K., 1996. Cytokine-stimulated astrocytes damage human
neurons via a nitric oxide mechanism. Glia 16, 276–284.
Chen, Y., Swanson, R.A., 2003. Astrocytes and brain injury.
J. Cereb. Blood Flow Metab. 23, 137–149.
Chiu, F.C., Goldman, J.E., 1984. Synthesis and turnover of
cytoskeletal proteins in cultured astrocytes. J. Neurochem. 42,
166–174.
Chizhikov, V.V., Millen, K.J., 2004. Control of roof plate formation
by Lmx1a in the developing spinal cord. Development 131,
2693–2705.
Choi, H.B., Gordon, G.R., Zhou, N., Tai, C., Rungta, R.L., Martinez,
J., Milner, T.A., Ryu, J.K., McLarnon, J.G., Tresguerres, M., et
al., 2012. Metabolic communication between astrocytes and
neurons via bicarbonate-responsive soluble adenylyl cyclase.
Neuron 75, 1094–1104.
Choi, S.S., Lee, H.J., Lim, I., Satoh, J., Kim, S.U., 2014. Human
astrocytes: secretome profiles of cytokines and chemokines.
PLoS One 9, e92325.
Davies, S.J., Shih, C.H., Noble, M., Mayer-Proschel, M., Davies, J.E.,
Proschel, C., 2011. Transplantation of specific human astrocytes
promotes functional recovery after spinal cord injury. PLoS One
6, e17328.
Deneen, B., Ho, R., Lukaszewicz, A., Hochstim, C.J., Gronostajski,
R.M., Anderson, D.J., 2006. The transcription factor NFIA controls
the onset of gliogenesis in the developing spinal cord. Neuron 52,
953–968.
Devine, M.J., Ryten, M., Vodicka, P., Thomson, A.J., Burdon, T.,
Houlden, H., Cavaleri, F., Nagano, M., Drummond, N.J., Taanman,
J.W., et al., 2011. Parkinson's disease induced pluripotent stem
cells with triplication of the alpha-synuclein locus. Nat. Commun.
2, 440.
Di Giorgio, F.P., Boulting, G.L., Bobrowicz, S., Eggan, K.C., 2008.
Human embryonic stem cell-derived motor neurons are sensitive
to the toxic effect of glial cells carrying an ALS-causing mutation.
Cell Stem Cell 3, 637–648.
Episcopo, F.L., Tirolo, C., Testa, N., Caniglia, S., Morale, M.C.,
Marchetti, B., 2013. Reactive astrocytes are key players in
nigrostriatal dopaminergic neurorepair in the MPTP mouse model
of Parkinson's disease: focus on endogenous neurorestoration.
Curr. Aging Sci. 6, 45–55.
Eroglu, C., Barres, B.A., 2010. Regulation of synaptic connectivity
by glia. Nature 468, 223–231.
Fischer, Y., Ganic, E., Ameri, J., Xian, X., Johannesson, M., Semb,
H., 2010. NANOG reporter cell lines generated by gene targeting
in human embryonic stem cells. PLoS One 5.
Gu, X.L., Long, C.X., Sun, L., Xie, C., Lin, X., Cai, H., 2010.
Astrocytic expression of Parkinson's disease-related A53T alpha-
synuclein causes neurodegeneration in mice. Mol. Brain 3, 12.
Haidet-Phillips, A.M., Hester, M.E., Miranda, C.J., Meyer, K., Braun,
L., Frakes, A., Song, S., Likhite, S., Murtha, M.J., Foust, K.D., et
al., 2011. Astrocytes from familial and sporadic ALS patients are
toxic to motor neurons. Nat. Biotechnol. 29, 824–828.
Han, X., Chen, M., Wang, F., Windrem, M., Wang, S., Shanz, S., Xu,
Q., Oberheim, N.A., Bekar, L., Betstadt, S., et al., 2013.
Forebrain engraftment by human glial progenitor cells enhances
synaptic plasticity and learning in adult mice. Cell Stem Cell 12,
342–353.
Hochstim, C., Deneen, B., Lukaszewicz, A., Zhou, Q., Anderson,
D.J., 2008. Identification of positionally distinct astrocyte subtypes
whose identities are specified by a homeodomain code. Cell 133,
510–522.
Hu, B.Y., Weick, J.P., Yu, J., Ma, L.X., Zhang, X.Q., Thomson, J.A.,
Zhang, S.C., 2010. Neural differentiation of human induced
pluripotent stem cells follows developmental principles but with
variable potency. Proc. Natl. Acad. Sci. U. S. A. 107, 4335–4340.
219Human astrocyte PSC reporter linesJiang, P., Chen, C., Wang, R., Chechneva, O.V., Chung, S.H., Rao,
M.S., Pleasure, D.E., Liu, Y., Zhang, Q., Deng, W., 2013. hESC-
derived Olig2+ progenitors generate a subtype of astroglia with
protective effects against ischaemic brain injury. Nat. Commun.
4, 2196.
Juopperi, T.A., Kim, W.R., Chiang, C.H., Yu, H., Margolis, R.L.,
Ross, C.A., Ming, G.L., Song, H., 2012. Astrocytes generated
from patient induced pluripotent stem cells recapitulate features
of Huntington's disease patient cells. Mol. Brain 5, 17.
Kiecker, C., Lumsden, A., 2012. The role of organizers in patterning
the nervous system. Annu. Rev. Neurosci. 35, 347–367.
Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J.,
Lundblad, M., Lindvall, O., Parmar, M., 2012a. Generation of
regionally specified neural progenitors and functional neurons
from human embryonic stem cells under defined conditions. Cell
Rep. 1, 703–714.
Kirkeby, A., Nelander, J., Parmar, M., 2012b. Generating regional-
ized neuronal cells from pluripotency, a step-by-step protocol.
Front. Cell. Neurosci. 6, 64.
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y.,
Imamura, K., Egawa, N., Yahata, N., Okita, K., et al., 2013.
Modeling Alzheimer's disease with iPSCs reveals stress pheno-
types associated with intracellular Abeta and differential drug
responsiveness. Cell Stem Cell 12, 487–496.
Krencik, R., Weick, J.P., Liu, Y., Zhang, Z.J., Zhang, S.C., 2011.
Specification of transplantable astroglial subtypes from human
pluripotent stem cells. Nat. Biotechnol. 29, 528–534.
Kriks, S., Shim, J.W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z.,
Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al., 2011.
Dopamine neurons derived from human ES cells efficiently engraft
in animal models of Parkinson's disease. Nature 480, 547–551.
Lamas, N.J., Johnson-Kerner, B., Roybon, L., Kim, Y.A., Garcia-
Diaz, A., Wichterle, H., Henderson, C.E., 2014. Neurotrophic
requirements of human motor neurons defined using amplified
and purified stem cell-derived cultures. PLoS One 9, e110324.
Lee, Y., Messing, A., Su, M., Brenner, M., 2008. GFAP promoter
elements required for region-specific and astrocyte-specific
expression. Glia 56, 481–493.
Lee, H.J., Suk, J.E., Patrick, C., Bae, E.J., Cho, J.H., Rho, S.,
Hwang, D., Masliah, E., Lee, S.J., 2010. Direct transfer of alpha-
synuclein from neuron to astroglia causes inflammatory re-
sponses in synucleinopathies. J. Biol. Chem. 285, 9262–9272.
Lee, M., McGeer, E., McGeer, P.L., 2013. Neurotoxins released from
interferon-gamma-stimulated human astrocytes. Neuroscience
229, 164–175.
Lek, M., Dias, J.M., Marklund, U., Uhde, C.W., Kurdija, S., Lei, Q.,
Sussel, L., Rubenstein, J.L., Matise, M.P., Arnold, H.H., et al.,
2010. A homeodomain feedback circuit underlies step-function
interpretation of a Shh morphogen gradient during ventral neural
patterning. Development 137, 4051–4060.
Lepore, A.C., Rauck, B., Dejea, C., Pardo, A.C., Rao, M.S.,
Rothstein, J.D., Maragakis, N.J., 2008. Focal transplantation-
based astrocyte replacement is neuroprotective in a model of
motor neuron disease. Nat. Neurosci. 11, 1294–1301.
Liu, Y., Jiang, P., Deng, W., 2011. OLIG gene targeting in human
pluripotent stem cells for motor neuron and oligodendrocyte
differentiation. Nat. Protoc. 6, 640–655.
Nelson, A.D., Suzuki, M., Svendsen, C.N., 2008. A high concentra-
tion of epidermal growth factor increases the growth and survival
of neurogenic radial glial cells within human neurosphere cultures.
Stem Cells 26, 348–355.
Oberheim, N.A., Takano, T., Han, X., He, W., Lin, J.H., Wang, F.,
Xu, Q., Wyatt, J.D., Pilcher, W., Ojemann, J.G., et al., 2009.
Uniquely hominid features of adult human astrocytes. J. Neurosci.
29, 3276–3287.
Pekny, M., Wilhelmsson, U., Pekna, M., 2014. The dual role of
astrocyte activation and reactive gliosis. Neurosci. Lett. 565,
30–38.Placantonakis, D.G., Tomishima, M.J., Lafaille, F., Desbordes, S.C., Jia,
F., Socci, N.D., Viale, A., Lee, H., Harrison, N., Tabar, V., et al.,
2009. BAC transgenesis in human embryonic stem cells as a novel
tool to define the human neural lineage. Stem Cells 27, 521–532.
Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P., Angot, E.,
2014. Alpha-synuclein transfers from neurons to oligodendro-
cytes. Glia 62, 387–398.
Ribes, V., Balaskas, N., Sasai, N., Cruz, C., Dessaud, E., Cayuso, J.,
Tozer, S., Yang, L.L., Novitch, B., Marti, E., et al., 2010. Distinct
Sonic Hedgehog signaling dynamics specify floor plate and ventral
neuronal progenitors in the vertebrate neural tube. Genes Dev. 24,
1186–1200.
Rostovskaya, M., Fu, J., Obst, M., Baer, I., Weidlich, S., Wang, H.,
Smith, A.J., Anastassiadis, K., Stewart, A.F., 2012. Transposon-
mediated BAC transgenesis in human ES cells. Nucleic Acids Res.
40, e150.
Rowitch, D.H., Kriegstein, A.R., 2010. Developmental genetics of
vertebrate glial-cell specification. Nature 468, 214–222.
Roybon, L., Lamas, N.J., Garcia-Diaz, A., Yang, E.J., Sattler, R.,
Jackson-Lewis, V., Kim, Y.A., Kachel, C.A., Rothstein, J.D.,
Przedborski, S., et al., 2013. Human stem cell-derived spinal
cord astrocytes with defined mature or reactive phenotypes.
Cell Rep. 4, 1035–1048.
Schuldiner, M., Yanuka, O., Itskovitz-Eldor, J., Melton, D.A.,
Benvenisty, N., 2000. Effects of eight growth factors on the
differentiation of cells derived from human embryonic stem
cells. Proc. Natl. Acad. Sci. U. S. A. 97, 11307–11312.
Semple, B.D., Frugier, T., Morganti-Kossmann, M.C., 2010. CCL2
modulates cytokine production in cultured mouse astrocytes.
J. Neuroinflammation 7, 67.
Serio, A., Bilican, B., Barmada, S.J., Ando, D.M., Zhao, C., Siller, R.,
Burr, K., Haghi, G., Story, D., Nishimura, A.L., et al., 2013.
Astrocyte pathology and the absence of non-cell autonomy in an
induced pluripotent stem cell model of TDP-43 proteinopathy.
Proc. Natl. Acad. Sci. U. S. A. 110, 4697–4702.
Shaltouki, A., Peng, J., Liu, Q., Rao, M.S., Zeng, X., 2013. Efficient
generation of astrocytes from human pluripotent stem cells in
defined conditions. Stem Cells 31, 941–952.
Simard, M., Nedergaard, M., 2004. The neurobiology of glia in
the context of water and ion homeostasis. Neuroscience 129,
877–896.
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L.,
Zeng, X., 2010. Efficient generation of functional dopaminergic
neurons from human induced pluripotent stem cells under
defined conditions. Stem Cells 28, 1893–1904.
Tsai, H.H., Li, H., Fuentealba, L.C., Molofsky, A.V., Taveira-
Marques, R., Zhuang, H., Tenney, A., Murnen, A.T., Fancy,
S.P., Merkle, F., et al., 2012. Regional astrocyte allocation
regulates CNS synaptogenesis and repair. Science 337, 358–362.
Waak, J., Weber, S.S., Waldenmaier, A., Gorner, K., Alunni-Fabbroni,
M., Schell, H., Vogt-Weisenhorn, D., Pham, T.T., Reumers, V.,
Baekelandt, V., et al., 2009. Regulation of astrocyte inflammatory
responses by the Parkinson's disease-associated gene DJ-1. FASEB
J. 23, 2478–2489.
Wakabayashi, K., Hayashi, S., Yoshimoto, M., Kudo, H., Takahashi,
H., 2000. NACP/alpha-synuclein-positive filamentous inclusions
in astrocytes and oligodendrocytes of Parkinson's disease brains.
Acta Neuropathol. 99, 14–20.
Wichterle, H., Przedborski, S., 2010. What can pluripotent stem
cells teach us about neurodegenerative diseases? Nat. Neurosci.
13, 800–804.
Yamanaka, K., Chun, S.J., Boillee, S., Fujimori-Tonou, N., Yamashita,
H., Gutmann, D.H., Takahashi, R., Misawa, H., Cleveland, D.W.,
2008. Astrocytes as determinants of disease progression in inherited
amyotrophic lateral sclerosis. Nat. Neurosci. 11, 251–253.
Yan, Y., Ding, X., Li, K., Ciric, B., Wu, S., Xu, H., Gran, B., Rostami,
A., Zhang, G.X., 2012. CNS-specific therapy for ongoing EAE by
silencing IL-17 pathway in astrocytes. Mol. Ther. 20, 1338–1348.
220 S. Holmqvist et al.Yuan, S.H., Martin, J., Elia, J., Flippin, J., Paramban, R.I.,
Hefferan, M.P., Vidal, J.G., Mu, Y., Killian, R.L., Israel, M.A.,
et al., 2011. Cell-surface marker signatures for the isolation of
neural stem cells, glia and neurons derived from human pluripo-
tent stem cells. PLoS One 6, e17540.Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., Wilson,
B., Zhang, W., Zhou, Y., Hong, J.S., et al., 2005. Aggregated
alpha-synuclein activates microglia: a process leading to disease
progression in Parkinson's disease. FASEB J. 19, 533–542.
